🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,061 results for “Bio” Clear

  1. Omega-3 fatty acids

    NORTHWEST BIOTHERAPEUTICS INC

    Metabolic Syndrome X

    phase 1 other active

    1 trial

  2. Omnitram

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule completed

    1 trial

  3. Open label, Phase I study to assess and compare the pharmacokinetic parameters after multiple oral administration of stiripentol 1000 mg in renal impaired patients and matching controls with normal renal function

    Biocodex

    Patients with renal impairement

    phase 1 other active

    1 trial

  4. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.

    Bioprojet Pharma

    narcolepsy with cataplexy, Narcolepsy

    phase 1 other active

    1 trial

  5. Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects

    Bioprojet Pharma

    Narcolepsy, Narcolepsy with cataplexy

    phase 1 other active

    1 trial

  6. Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.

    Bioprojet Pharma

    Binge eating disorder

    phase 1 other active

    1 trial

  7. Open-label, randomized, two-treatment, two-period, two-sequence, cross-over, single dose, bioequivalence study comparing ISOPRINOSINE® FORTE 100 mg/mL Syrup to ISOPRINOSINE® 500 mg tablets in healthy male and female subjects under fasting conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a bioequivalence study)

    phase 1 other active

    1 trial

  8. Opicapone

    NEUROCRINE BIOSCIENCES INC

    Parkinson Disease

    phase 1 small molecule completed

    1 trial

  9. Opioid Agonist

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 1 small molecule completed

    1 trial

  10. Oral methylphenidate and Oral haloperidol

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 1 small molecule completed

    1 trial

  11. Original formulation EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 1 small molecule completed

    1 trial

  12. Oshadi Oral Insulin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes

    phase 1 small molecule completed

    1 trial

  13. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  14. Outpatient MST/OPTION-A

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 1 other completed

    1 trial

  15. Oxcarbazepine (brand name vs generic drugs)

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule completed

    1 trial

  16. OxyCODONE 5 mg Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 1 small molecule active

    1 trial

  17. Oxycodone

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 1 small molecule completed

    1 trial

  18. Oxycodone IN

    BRIGHT MINDS BIOSCIENCES INC.

    Physiologically Based Pharmacokinetic

    phase 1 small molecule completed

    1 trial

  19. Oxycodone Medication First

    BRIGHT MINDS BIOSCIENCES INC.

    Prescription Drug Abuse (Not Dependent)

    phase 1 small molecule completed

    1 trial

  20. Oxycodone and Midazolam

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercapnia

    phase 1 small molecule completed

    1 trial

  21. PA-824 1000 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  22. PA-824 200mg

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 1 small molecule completed

    1 trial

  23. PAN-301-1

    Sensei Biotherapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

  24. PARP inhibitor BMN-673

    BioMarin Pharmaceutical Australia Pty Ltd

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources